key: cord-0734859-h4d571ny
authors: da Fonseca, Leonardo; Carrilho, Flair José
title: Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS‐Cov‐2?
date: 2020-05-30
journal: Liver Int
DOI: 10.1111/liv.14545
sha: dde9b9b414204f8490c681a4678fa20c43f05763
doc_id: 734859
cord_uid: h4d571ny

We read with interest the editorial by Sharma and Pinato on the management of hepatocellular carcinoma (HCC) in the time of SARS-Cov-2 (1). The points raised by the authors will be of paramount importance to guide HCC groups worldwide.

Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS-Cov-2?

To the Editor We read with interest the editorial by Sharma and Pinato on the management of hepatocellular carcinoma (HCC) in the time of SARS-Cov-2. 1 The points raised by the authors will be of paramount importance to guide HCC groups worldwide.

Once there is no evidence suggesting that tyrosine kinase inhibitors (TKIs) increase the risk of COVID-19, the balance favours towards continuing TKIs for advanced-HCC patients who are likely to benefit from treatment. The approach to treat with a 50% dose 

LGdF has received lectures fees from Bayer and Roche. 

Management of hepatocellular cancer in the time of SARS-CoV-2

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and metaanalysis

Mechanisms of adverse effects of anti-VEGF therapy for cancer